Arnuity Ellipta Powder
Product Images NDC 0173-0888

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Arnuity Ellipta (NDC 0173-0888). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Furoate Chemical Structure (Arnuityellipta Spl Graphic 01)

Chemical structure diagram of the active ingredient fluticasone furoate shown as a detailed molecular formula with labeled atoms and bonds.*

FDA Label Image

Figure 1. Impact Of Intrinsic Factors On The Pharmacokinetics (pk) Of Fluticasone Furoate (ff) (Arnuityellipta Spl Graphic 02)

A chart titled Impact of Intrinsic Factors on Fluticasone Furoate PK showing fold changes and 90% confidence intervals for AUC and Cmax across different populations (age, ethnicity, gender, renal and hepatic impairment). Recommendations range from no dose adjustment to caution based on factor severity.*

FDA Label Image

Figure 2. Impact Of Coadministered Ketoconazolea On The Pharmacokinetics (pk) Of Fluticasone Furoate (Arnuityellipta Spl Graphic 03)

A chart illustrating the impact of the interacting drug Ketoconazole on the pharmacokinetics (PK) of fluticasone furoate, showing fold changes and 90% confidence intervals for area under curve (AUC) and maximum concentration (Cmax) relative to a reference, with a recommendation of caution.*

FDA Label Image

Figure 3. Dose-ranging Trials (Arnuityellipta Spl Graphic 04)

A clinical trial figure showing differences from placebo with 95% confidence intervals for three trials (687, 685, and 684). The x-axis shows treatment doses in micrograms (FF and FP labels), and the y-axis shows differences from placebo and confidence intervals. Each trial's data points with error bars illustrate treatment effects with inhaled fluticasone furoate (FF) and fluticasone propionate (FP).*

FDA Label Image

Figure 4. Mean Change From Baseline In Individual Serial Fev1 (ml) Assessments After 12 Weeks Of Treatment – Trial 2 (Arnuityellipta Spl Graphic 05)

A line graph depicting the least squares mean change from baseline in mL over a 24-hour period after dosing. It compares Arnuity Ellipta 100 mcg once daily with placebo, showing higher values consistently for Arnuity Ellipta across the time points measured.*

FDA Label Image

Figure 5. Mean Change From Baseline In Trough Fev1 (ml) Over Time – Trial 3 (Arnuityellipta Spl Graphic 06)

A line graph showing the least squares mean change from baseline in mL on the y-axis and the week of study on the x-axis for Arnuity Ellipta 200 mcg once daily and 100 mcg once daily. Two lines track the measurements over 24 weeks of study for these two strengths of Arnuity Ellipta powder for respiratory inhalation by GlaxoSmithKline LLC.*

FDA Label Image

Figure 6. Mean Change From Baseline In Individual Serial Fev1 (ml) Assessments After 24 Weeks Of Treatment – Trial 4 (Arnuityellipta Spl Graphic 07)

A line graph comparing the LS mean change from baseline in mL over planned time since dose (hours) for Arnuity Ellipta 200 mcg once daily and fluticasone propionate 500 mcg twice daily. The graph includes error bars indicating variability around the mean values for each time point up to 24 hours.*

FDA Label Image

Parts Figure (Arnuityellipta Spl Graphic 08)

An exploded diagram illustrating the packaging components of Arnuity Ellipta inhaler. It shows the carton, tray, tray lid, desiccant packet, the inhaler device itself, and patient information leaflet, each labeled to depict the contents and arrangement within the package.*

FDA Label Image

Pil Figure A (Arnuityellipta Spl Graphic 09)

An instructional illustration showing a hand peeling back a foil seal on a blister pack, presumably for accessing powder inhalation medication capsules such as those used in Arnuity Ellipta. The focus is on the step of opening the sealed blister tray to retrieve the capsule.*

FDA Label Image

Pil Figure B (Arnuityellipta Spl Graphic 10)

An instructional diagram showing a packet being discarded into a trash can. The illustration demonstrates proper disposal of a used or empty unit-dose packet, associated with Arnuity Ellipta inhalation powder by GlaxoSmithKline LLC.*

FDA Label Image

Pil Figure C (Arnuityellipta Spl Graphic 11)

An instructional diagram of the Arnuity Ellipta inhaler device, showing the cover and the dose counter displaying '30'. The image highlights key external features relevant to device use.*

FDA Label Image

Pil Figure D (Arnuityellipta Spl Graphic 12)

An instructional diagram showing how to open the cover of a respiratory inhaler device, highlighting parts labeled as mouthpiece, air vent, counter, and cover with an arrow indicating the cover opens with a 'Click' sound.*

FDA Label Image

Pil Figure E (Arnuityellipta Spl Graphic 13)

An instructional diagram showing a person using an inhaler device. The person is holding the inhaler near their mouth and exhaling, depicted by a series of arrows moving away from the mouth to demonstrate the breath out before inhaling the medication.*

FDA Label Image

Pil Figure F (Arnuityellipta Spl Graphic 14)

Illustration showing hands holding the Arnuity Ellipta inhaler device close to the mouth, demonstrating how to position the inhaler for respiratory (inhalation) use. The user’s fingers are gripping the inhaler while the mouth is placed near the mouthpiece.*

FDA Label Image

Pil Figure G (Arnuityellipta Spl Graphic 15)

Instructional illustration showing hands holding an Arnuity Ellipta inhaler, with emphasis on not blocking the air vent with fingers to ensure proper use of the respiratory powder inhalation device.*

FDA Label Image

Pil Figure H (Arnuityellipta Spl Graphic 16)

Illustration showing the side profile of a person holding their breath for 3-4 seconds, indicated by a clock and accompanying text. The image demonstrates a step related to inhalation or respiratory administration, likely for proper use of a powdered inhaler device.*

FDA Label Image

Pil Figure I (Arnuityellipta Spl Graphic 17)

An instructional illustration showing a person using an Arnuity Ellipta inhaler. The person holds the device near their mouth and is depicted exhaling or inhaling with directional arrows indicating proper respiratory inhalation technique.*

FDA Label Image

Pil Figure J (Arnuityellipta Spl Graphic 18)

An instructional diagram showing the Arnuity Ellipta inhaler device with the mouthpiece cover being opened upwards, indicated by a black arrow. The device surface includes a dose counter displaying the number 29, demonstrating part of its use for respiratory (inhalation) administration of fluticasone furoate powder.*

FDA Label Image

Pil Figure K (Arnuityellipta Spl Graphic 19)

An instructional illustration showing a person exhaling near a sink with a glass of water placed on the counter, possibly demonstrating part of a medication administration or inhalation technique.*

FDA Label Image

Pil Figure L (Arnuityellipta Spl Graphic 20)

Illustration of the Arnuity Ellipta inhaler device showing a view of the mouthpiece cover partially open. The image highlights a red numerical dose counter window on the device, indicating the remaining number of doses available in the inhaler.*

FDA Label Image

Arnuity Ellipta 100mcg 30 Count Carton (Arnuityellipta Spl Graphic 21)

Arnuity Ellipta 50 mcg (fluticasone furoate inhalation powder) label with orange and white color scheme showing the inhaler device. The label indicates each blister contains 50 mcg of fluticasone furoate and lactose monohydrate. Package includes 1 Ellipta inhaler containing 1 foil strip of 30 blisters. Labeler is GlaxoSmithKline LLC.*

FDA Label Image

Arnuity Ellipta 200mcg 30 Count Carton (Arnuityellipta Spl Graphic 22)

Packaging label for Arnuity Ellipta 100 mcg powder for oral inhalation, containing fluticasone furoate. The label shows a single Ellipta inhaler with one foil strip of 30 blisters. The product is a prescription respiratory inhalation powder manufactured by GlaxoSmithKline LLC. The label includes dosage strength and usage instructions.*

FDA Label Image

Arnuityellipta Spl Graphic 23

Arnuity Ellipta 200 mcg inhalation powder packaging label for oral inhalation. The label indicates the active ingredient fluticasone furoate and shows the inhaler device with a foil strip containing 30 blisters. The product is labeled for prescription use only and manufactured by GlaxoSmithKline LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.